CD4 and neoplasm: Our data suggest that CD4+ T cells contribute to better outcomes in patients with PDAC, which may be mediated through their direct cytotoxicity against tumor cells and action as helper cells to potentiate dendritic cells, resulting in enhanced CD8+ T cell responses [21].